| Literature DB >> 19933829 |
Bernt Christian Hellerud1, Audun Aase, Tove Karin Herstad, Lisbeth Meyer Naess, Lisa Høyem Kristiansen, Anne-Marie Siebke Trøseid, Morten Harboe, Knut Tore Lappegård, Petter Brandtzaeg, E Arne Høiby, Tom Eirik Mollnes.
Abstract
Certain complement defects are associated with an increased propensity to contract Neisseria meningitidis infections. We performed detailed analyses of complement-mediated defense mechanisms against N. meningitidis 44/76 with whole blood and serum from two adult patients who were completely C2 or C5 deficient. The C5-deficient patient and the matched control were also deficient in mannose-binding lectin (MBL). The proliferation of meningococci incubated in freshly drawn whole blood was estimated by CFU and quantitative DNA real-time PCR. The serum bactericidal activity and opsonophagocytic activity by granulocytes were investigated, including heat-inactivated postvaccination sera, to examine the influence of antimeningococcal antibodies. The meningococci proliferated equally in C2- and C5-deficient blood, with a 2 log(10) increase of CFU and 4- to 5-log(10) increase in DNA copies. Proliferation was modestly decreased in reconstituted C2-deficient and control blood. After reconstitution of C5-deficient blood, all meningococci were killed, which is consistent with high antibody titers being present. The opsonophagocytic activity was strictly C2 dependent, appeared with normal serum, and increased with postvaccination serum. Serum bactericidal activity was strictly dependent on C2, C5, and high antibody titers. MBL did not influence any of the parameters observed. Complement-mediated defense against meningococci was thus dependent on the classical pathway. Some opsonophagocytic activity occurred despite low levels of antimeningococcal antibodies but was more efficient with immune sera. Serum bactericidal activity was dependent on C2, C5, and immune sera. MBL did not influence any of the parameters observed.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19933829 PMCID: PMC2812193 DOI: 10.1128/IAI.01044-09
Source DB: PubMed Journal: Infect Immun ISSN: 0019-9567 Impact factor: 3.441